A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 148-156

  Bryant, J L ^a   Britson, J ^a   Balko, J M ^a   Willian, M ^a   Timmons, R ^a   Frolov, A ^b   Black, E P ^a,c  

^a University of Kentucky   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

biomarker; invasion; metastasis; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MICRORNA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; LUNG NON SMALL CELL CANCER; METASTASIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84855359334     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.465     Document Type: Article

References (35)

1. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15(16): 5060-5072
2. Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development 132(21): 4653-4662 (Pubitemid 41685276)
3. Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP (2006) Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 7: 289
4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2): 281-297
5. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP (2008) Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5): 1478-1486 (Pubitemid 351413932)
6. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9(6): 582-589 (Pubitemid 351772923)
7. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8(9): 1207-1216
8. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn Jr PA (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4(8): 521-528 (Pubitemid 44341362)
9. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn Jr PA (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4(8): 521-528 (Pubitemid 44341362)
10. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29(2): 117-129 (Pubitemid 32952643)
11. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25): 5900-5909
12. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9(2): 102-114
13. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn Jr PA, Raben D (2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6(6): 1683-1691 (Pubitemid 46954044)
14. Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH (2007) Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 13(12): 3713-3723 (Pubitemid 46955136)
15. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM (2009) Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23(18): 2140-2151
16. Haddad Y, Choi W, McConkey DJ (2009) Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 15(2): 532-542
17. Hagen JW, Lai EC (2008) microRNA control of cell-cell signaling during development and disease. Cell Cycle 7(15): 2327-2332
18. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043): 834-838 (Pubitemid 40839735)
19. Marinescu VD, Kohane IS, Riva A (2005) The MAPPER database: a multi-genome catalog of putative transcription factor binding sites. Nucleic Acids Res 33(Database issue): D91-D97 (Pubitemid 40207837)
20. Mongroo PS, Rustgi AK (2010) The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 10(3): 219-222
21. Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, Morrisey EE (2011) Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest 121(5): 1935-1945
22. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23(11): 2556-2568
23. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7): 894-907 (Pubitemid 351482843)
24. Patton LL, Pollack S, Wellner RB (1991) Responsiveness of a human parotid epithelial cell line (HSY) to autonomic stimulation: muscarinic control of K+ transport. In Vitro Cell Dev Biol 27A(10): 779-785
25. Polyak K, Shipitsin M, Campbell-Marrotta L, Bloushtain-Qimron N, Park SY (2009) Breast tumor heterogeneity: causes and consequences. Breast Cancer Res 11(Suppl 1): S18
26. Reich M, Ohm K, Angelo M, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38(5): 500-501
27. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6): 1101-1108 (Pubitemid 351818697)
28. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2): 131-142 (Pubitemid 43278296)
29. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65(20): 9455-9462 (Pubitemid 41508014)
30. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, Shyr Y, Kasper S, Case T, Roberts RL, Shappell SB, Moses HL, Matusik RJ (2003) The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 5(3): 267-277 (Pubitemid 36754056)
31. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ, Arnoletti JP (2007) Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141(4): 464-469 (Pubitemid 46441307)
32. Wendt MK, Tian M, Schiemann WP (2011) Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res
33. Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer 43(10): 1529-1544 (Pubitemid 46901017)
34. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R (2010) TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107(35): 15535-15540
35. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11(24 Pt 1): 8686-8698 (Pubitemid 43005918)